These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32272770)

  • 1. Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes.
    Stetka J; Gursky J; Liñan Velasquez J; Mojzikova R; Vyhlidalova P; Vrablova L; Bartek J; Divoky V
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32272770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation.
    Stetka J; Vyhlidalova P; Lanikova L; Koralkova P; Gursky J; Hlusi A; Flodr P; Hubackova S; Bartek J; Hodny Z; Divoky V
    Oncogene; 2019 Jul; 38(28):5627-5642. PubMed ID: 30967632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.
    Nieborowska-Skorska M; Kopinski PK; Ray R; Hoser G; Ngaba D; Flis S; Cramer K; Reddy MM; Koptyra M; Penserga T; Glodkowska-Mrowka E; Bolton E; Holyoake TL; Eaves CJ; Cerny-Reiterer S; Valent P; Hochhaus A; Hughes TP; van der Kuip H; Sattler M; Wiktor-Jedrzejczak W; Richardson C; Dorrance A; Stoklosa T; Williams DA; Skorski T
    Blood; 2012 May; 119(18):4253-63. PubMed ID: 22411871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
    Masykura N; Habibah U; Selasih SF; Gani S; Irawan C; Somoastro S; Handoyo Utomo AR
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):220-227. PubMed ID: 30772299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.
    Shi XB; Jiang JF; Jin FX; Cheng W
    World J Clin Cases; 2019 May; 7(9):1087-1092. PubMed ID: 31123683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms.
    Berzoti-Coelho MG; Ferreira AF; de Souza Nunes N; Pinto MT; Júnior MC; Simões BP; Martínez-A C; Souto EX; Panepucci RA; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2016 Jul; 59():25-30. PubMed ID: 27282563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.
    Vainchenker W; Constantinescu SN
    Hematology Am Soc Hematol Educ Program; 2005; ():195-200. PubMed ID: 16304380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms.
    Bisen A; Claxton DF
    Adv Exp Med Biol; 2013; 779():179-96. PubMed ID: 23288640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.
    Marty C; Lacout C; Droin N; Le Couédic JP; Ribrag V; Solary E; Vainchenker W; Villeval JL; Plo I
    Leukemia; 2013 Nov; 27(11):2187-95. PubMed ID: 23558526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
    Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
    J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of tumor progression in chronic myeloproliferative disorders.
    Gaidano G; Guerrasio A; Serra A; Rege-Cambrin G; Saglio G
    Leukemia; 1994 Apr; 8 Suppl 1():S27-9. PubMed ID: 8152300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
    Brusa G; Benvenuti M; Mazzacurati L; Mancini M; Pattacini L; Martinelli G; Barbieri E; Greenberger JS; Baccarani M; Santucci MA
    Haematologica; 2003 Jun; 88(6):622-30. PubMed ID: 12801837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
    Yoo JH; Park TS; Maeng HY; Sun YK; Kim YA; Kie JH; Cho EH; Song J; Lee KA; Suh B; Choi JR
    Cancer Genet Cytogenet; 2009 Feb; 189(1):43-7. PubMed ID: 19167611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.
    Pinilla-Ibarz J; Sweet KL; Corrales-Yepez GM; Komrokji RS
    Onco Targets Ther; 2016; 9():4937-57. PubMed ID: 27570458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera.
    Tsuruta-Kishino T; Koya J; Kataoka K; Narukawa K; Sumitomo Y; Kobayashi H; Sato T; Kurokawa M
    Oncogene; 2017 Jun; 36(23):3300-3311. PubMed ID: 28068330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
    Cornea MI; Levrat E; Pugin P; Betticher DC
    J Med Case Rep; 2015 Apr; 9():30. PubMed ID: 26187587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.